Treatment of COVID-19 with remdesivir in the absence of humoral immunity
Matthew S. Buckland,
James B. Galloway,
Caoimhe Nic Fhogartaigh,
Luke Meredith,
Nicholas M. Provine,
Stuart Bloor,
Ane Ogbe,
Wioleta M. Zelek,
Anna Smielewska,
Anna Yakovleva,
Tiffeney Mann,
Laura Bergamaschi,
Lorinda Turner,
Frederica Mescia,
Erik J. M. Toonen,
Carl-Philipp Hackstein,
Hossain Delowar Akther,
Vinicius Adriano Vieira,
Lourdes Ceron-Gutierrez,
Jimstan Periselneris,
Sorena Kiani-Alikhan,
Sofia Grigoriadou,
Devan Vaghela,
Sara E. Lear,
M. Estée Török,
William L. Hamilton,
Joanne Stockton,
Josh Quick,
Peter Nelson,
Michael Hunter,
Tanya I. Coulter,
Lisa Devlin,
John R. Bradley,
Kenneth G. C. Smith,
Willem H. Ouwehand,
Lise Estcourt,
Heli Harvala,
David J. Roberts,
Ian B. Wilkinson,
Nick Screaton,
Nicholas Loman,
Rainer Doffinger,
Paul A. Lyons,
B. Paul Morgan,
Ian G. Goodfellow,
Paul Klenerman,
Paul J. Lehner,
Nicholas J. Matheson,
James E. D. Thaventhiran
Dec 22, 2020
Abstract: The response to the coronavirus disease 2019 (COVID-19) pandemic has been hampered by lack of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral therapy. Here we report the use of...